New hope for chinese patients with Hard-to-Treat blood cancers
NCT ID NCT03932331
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a drug called acalabrutinib in Chinese adults with certain blood cancers (mantle cell lymphoma, chronic lymphocytic leukemia, or other B-cell cancers) that have come back or not responded to treatment. The trial has two parts: the first checks safety and how the drug moves through the body, and the second looks at how well it shrinks tumors. About 105 participants will take acalabrutinib pills twice a day.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
acalabrutinib (a targeted cancer drug taken as a pill)
What this could lead to
If successful, this could provide a new treatment option for Chinese patients with certain blood cancers that have not responded to prior therapy.
What could go wrong
This is an early-phase study (Phase 1/2) with a small number of participants, so results may not apply broadly. Side effects are possible, and the drug may not work for everyone.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PHASE I: RELAPSED OR REFRACTORY B-CELL MALIGNANCIES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research Site
Beijing, 100044, China
-
Research Site
Beijing, 100142, China
-
Research Site
Beijing, 100191, China
-
Research Site
Changchun, 130021, China
-
Research Site
Changsha, 410008, China
-
Research Site
Changzhou, 272100, China
-
Research Site
Chengdu, 610041, China
-
Research Site
Fuzhou, China
-
Research Site
Haikou, 570311, China
-
Research Site
Hangzhou, 310003, China
-
Research Site
Hangzhou, 310022, China
-
Research Site
Harbin, 150049, China
-
Research Site
Hefei, 230031, China
-
Research Site
Hohhot, 10050, China
-
Research Site
Nanchang, 330006, China
-
Research Site
Nanjing, 210029, China
-
Research Site
Shanghai, 200032, China
-
Research Site
Suzhou, 215006, China
-
Research Site
Tianjin, 300020, China
-
Research Site
Tianjin, 300060, China
-
Research Site
Ürümqi, 830054, China
-
Research Site
Xining, 810007, China
-
Research Site
Zhengzhou, 450008, China